Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 12/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20704911 | 0.90 | CFTR (0.60) | BACE1CFTRMAOBLMNAGABRA1 | |
| SCHEMBL30309870 | 0.90 | CFTR (0.60) | BACE1CFTRMAOBLMNAGABRA1 | |
| SCHEMBL20704870 | 0.88 | CFTR (0.45) | BACE1CFTRMAOBGABRA1GABRB1 | |
| SCHEMBL20704848 | 0.88 | LMNA (0.51) | BACE1CFTRMAOBLMNAGABRA1 | |
| SCHEMBL20710980 | 0.81 | LMNA (0.49) | CFTRMAOBLMNA | |
| SCHEMBL20704754 | 0.78 | CFTR (0.43) | BACE1CFTRMAOBGABRA1GABRB1 | |
| SCHEMBL20704886 | 0.77 | CFTR (0.44) | BACE1CFTRMAOBGABRA1GABRB1 | |
| SCHEMBL20704811 | 0.77 | KMT2A (0.52) | BACE1CFTRMAOBLMNA | |
| SCHEMBL20704888 | 0.77 | CFTR (0.60) | BACE1CFTRMAOBLMNAGABRA1 | |
| SCHEMBL20704809 | 0.76 | POLB (0.51) | BACE1CFTRMAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113225-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230103887-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| WO-2022098879-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2020227437-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3664822-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | Axial Biotherapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019028456-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028456-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103887-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | BACE1 19/4885CFTR 2168/4885SNCA 1/4885 |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | SNCA, PARK7, PRNP | BACE1 19/4885CFTR 2168/4885SNCA 1/4885 |
| US-20230113225-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | BACE1 17/4885CFTR 2182/4885SNCA 1/4885 |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | BACE1 154/4885CFTR 760/4885SNCA 2/4885 |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | BACE1 154/4885CFTR 760/4885SNCA 2/4885 |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | BACE1 19/4885CFTR 2168/4885SNCA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.